Welcome to Alligator Bioscience

Alligator Bioscience discovers and develops innovative antibody based immunotherapies for the treatment of cancer. Alligator Drug Discovery and Development span early research phases with lead identification up to proof of concept phase I/II clinical studies in cancer patients. Alligator´s proprietary technology platforms includes the human antibody library ALLIGATOR-GOLD®  and the protein optimization technology FIND®. Alligator’s pipeline counts three immuno-oncology projects: ADC-1013 is a CD40 agonistic human monoclonal antibody in clinical phase I.  ADC-1015 is a bispecific antibody directed towards OX40 and CTLA-4 and is currently in pre-clinical phase, and ADC-1016 is a bispecific immuno-oncology project in research phase.

Latest News

20
May
2016

Alligator receives the SwedenBIO Award!

Alligator Bioscience has received the SwedenBIO Award for ”exceptional achievements within the life-science industry”. This is yet another conf

22
Apr
2016

First milestone payment for ADC-1013

Alligator Bioscience receives milestone payment from the CD40 Agonistic Immuno-Oncology Antibody ADC-1013 project with Johnson & Johnson Innovation

30
Mar
2016

Documentation of proposals for the annual shareholder’s meeting

Annual Report ver 2 2015 Alligator Bioscience After proofreading minor corrections has been made. Comprehensive income and Financial position are

23
Mar
2016

Notice of annual shareholders’ meeting in Alligator Bioscience AB

The shareholders of Alligator Bioscience AB, Reg. No 556597-8201, are hereby invited to attend the annual shareholders’ meeting to be held on Wed

04
Mar
2016

Communication of proposals for the extraordinary shareholder’s meeting on 14 March, 2016

Major shareholders have now submitted their proposals regarding items 8 and 9 in the published notice. Proposal item 8: The number of board memb

15
Feb
2016

Notice of extraordinary shareholders’ meeting in Alligator Bioscience AB

The shareholders of Alligator Bioscience AB (publ), Reg. No 556597-8201, are hereby invited to attend the extraordinary shareholder’s meeting to

01
Oct
2015

Alligator Bioscience Announces Approval of Collaboration Agreement with Johnson & Johnson Innovation by the US Federal Trade Commission

Alligator Bioscience AB, a privately held Swedish biotech company developing immuno-oncology antibodies for directed immunotherapy of cancer, today

12
Aug
2015

Alligator Bioscience Announces Collaboration with Johnson & Johnson Innovation for the CD40 Agonistic Immuno-Oncology Antibody ADC-1013

Alligator Bioscience AB, a privately held Swedish biotech company developing immuno-oncology antibodies for directed immunotherapy of cancer, today

12
May
2015

Alligator Bioscience featured in article by Invest in Skåne

Link to article published on 4 May 2015: http://www.investinskane.com/making-immunotherapy-game-changer-fight-against-cancer...

12
May
2015

Alligator Bioscience nyemission har avslutats

12 maj, 2015 – Nyemissionen i Alligator Bioscience AB är nu avslutad. Teckningstiden löpte ut den 14 april 2015. Nyemissionen riktade sig i fö

04
May
2015

Kallelse till årsstämma i Alligator Bioscience AB

Kallelse till årsstämma i Alligator Bioscience AB Länk till Kallelse Länk till Fullmakt 2015 Länk till Alligator Bioscience Årsredo

27
Apr
2015

First Patient Dosed by Alligator Bioscience in a Clinical Phase 1 Multicenter Trial

First Patient Dosed by Alligator Bioscience in a Clinical Phase 1 Multicenter Trial in Advanced Solid Tumors with the CD40 Agonistic Immuno-Oncolog

07
Apr
2015

Alligator Bioscience Starts a Clinical Phase 1 Multicenter Trial

Alligator Bioscience Starts a Clinical Phase 1 Multicenter Trial in Advanced Solid Tumors with the CD40 Agonistic Immuno-Oncology Antibody ADC-1013

17
Mar
2015

Teckningstiden i nyemissionen förlängd till den 14 april

Styrelsen i Alligator Bioscience har beslutat att förlänga teckningstiden i den pågående nyemissionen fram till den 14 april. Avräkningsnotor

25
Feb
2015

Alligator Bioscience har tagit in 54 miljoner i en riktad emission

Inom kort behandlas de första försökspersonerna med Alligators Bioscience’s antikroppsbaserade cancerpreparat ADC-1013. För att bekosta mulit

25
Feb
2015

Alligator Bioscience AB genomför nyemission

Den 25 februari 2015 beslutade styrelsen i Alligator Bioscience AB att genomföra en nyemission. Kursen för emissionen är 12 kr. Teckning av akti

20
Nov
2014

Alligator Bioscience AB får 2,1 miljoner kronor från VINNOVA för identifiering av nya immunmodulerande målmolekyler för immunterapi av cancer

Immunterapi av cancer har tydligt visat stor potential både kliniskt och kommersiellt, men antalet identifierade målmolekyler är i dagsläget n

27
May
2014

Alligator Bioscience AB återfår fullt ägande av läkemedelskandidat ADC-1013

Alligator Bioscience AB återfår fullt ägande av läkemedelskandidat ADC-1013 Alligator Bioscience AB har återfått fullt ägande av läkemed

14
May
2014

Kallelse till årsstämma i Alligator Bioscience AB

Kallelse till årstämma i Alligator Bioscience AB Aktieägarna i Alligator Bioscience AB (publ) kallas till årsstämma onsdagen den 11 juni 20

14
Jan
2014

Alligator Bioscience AB stärker sin finansiella position väsentligt

Alligator Bioscience AB stärker sin finansiella position väsentligt Under året 2013 har Alligator Bioscience AB tillförts ca 112 MSEK från b

13
Nov
2013

Alligator Bioscience AB genomför företrädresemission

Alligator Bioscience AB genomför företrädresemission Den 13 November beslutade styrelsen i Alligator Bioscience AB att genomföra en företr

22
Oct
2013

Kallelse till extra bolagsstämma i Alligator Bioscience AB

Kallelse till extra bolagsstämma i Alligator Bioscience AB Aktieägarna i Alligator Bioscience AB (publ) kallas till extra bolagsstämma den 5

18
Oct
2013

Alligator Bioscience AB förvärvar Atlas Therapeutics AB

Alligator Bioscience AB förvärvar Atlas Therapeutics AB och genomför riktad emission om 40 mkr till ett av Investor AB helägt dotterbolag

22
Sep
2013

Kallelse till extra bolagsstämma i Alligator Bioscience AB

Kallelse till extra bolagsstämma i Alligator Bioscience AB Aktieägarna i Alligator Bioscience AB (publ) kallas till extra bolagsstämma den

03
May
2013

Extension of the subscription period in the ongoing share issue

The Board of Alligator Bioscience AB has decided in accordance with the terms of issuance to extend the subscription period to May 27th, 2013. Paym

30
Apr
2013

Kallelse till Årsstämma i Alligator Bioscience AB

Aktieägarna i Alligator Bioscience AB (publ) kallas till årsstämma tisdagen den 28 maj 2013, kl. 13.00, i bolagets lokaler, Medicon Village, Sch

19
Apr
2013

Extension of the subscription period in the ongoing share issue

Extension of the subscription period in the ongoing share issue The Board of Alligator Bioscience AB has decided in accordance with the terms of i

05
Apr
2013

Extension of the subscription period in the ongoing share issue

The Board of Alligator Bioscience AB has decided in accordance with the terms of issuance to extend the subscription period to April 19th, 2013. Pa

12
Mar
2013

Alligator Bioscience AB genomför riktad nyemission

Efter mandat på extra bolagsstämma per den 18 februari 2013 har styrelsen i Alligator Bioscience AB beslutat att genomföra en riktad nyemission

28
Nov
2012

Alligator Bioscience joins European expert teams in an EU-funded training program

Alligator Bioscience announces today that the company is joining seven European expert teams in an EU-funded training program for analysis of the T

12
Nov
2012

Alligator Bioscience moves to Medicon Village in Lund, Sweden

Alligator Bioscience AB announces today that it has moved to Medicon Village. Following several years of constant growth the company has moved to

20
Aug
2012

Alligator Bioscience enters into research agreement with a Swedish biotech company

Alligator Bioscience enters into research agreement with a Swedish biotech company to develop novel medical products Lund, Sweden– August 20

20
Jun
2012

Alligator Bioscience AB har tagit in nytt kapital

Alligator Bioscience AB meddelar att man genom en första del av en emission tagit in ca 20 MSEK från befintliga ägare, till en kurs av 10 kr per

13
Jun
2012

Cobra Biologics Ltd. and Alligator Bioscience Sign Manufacturing Agreement

Cobra Biologics Ltd. and Alligator Bioscience Sign Monoclonal Antibody Manufacturing Agreement Cobra Biologics Ltd. posted yesterday on their

14
May
2012

Extension of the subscription period in the ongoing rights issuance

Board of Alligator Bioscience AB has decided in accordance with the terms of issuance to extend the subscription period, with and without preferent

14
May
2012

Kallelse till årsstämma i Alligator Bioscience AB

Aktieägarna i Alligator Bioscience AB (publ) kallas till årsstämma måndagen den 18 juni 2012, kl. 17.00, i bolagets lokaler, Scheelevägen 19A

23
Apr
2012

Alligator Bioscience AB genomför företrädresemission

Den 13 april beslutade styrelsen i Alligator Bioscience AB att genomföra en företrädesemission till befintliga aktieägare. Kursen för emissi

28
Mar
2012

Kallelse till extra bolagsstämma i Alligator Bioscience AB

Aktieägarna i Alligator Bioscience AB (publ) kallas till extra bolagsstämma 11 april 2012, kl. 10.00, i bolagets lokaler, Scheelevägen 19A i Lun

19
Dec
2011

Project Update on ADC-1004

Drug Development Candidate ADC-1004 has been shown to reduce myocardial infarction in a porcine ischemia reperfusion injury model. As part of the d

04
Jul
2011

Alligator Bioscience AB har tagit in ytterligare kapital

Alligator Bioscience AB meddelade tidigare i år att man genom riktade emissioner tagit in kapital från i huvudsak nya ägare. Därefter har Allig

09
Jun
2011

Peter Benson invald i styrelsen för Alligator Bioscience AB

Vid den ordinarie bolagstämman, som hölls den 9 juni 2011, valdes Peter Benson in i styrelsen för Alligator Bioscience AB. Peter Benson företr

09
Jun
2011

Förlängning av teckningstiden i pågående företrädesemission

Styrelsen i Alligator Bioscience AB beslutade idag i enlighet med emissionsvillkoren att förlänga tiden för teckning, med och utan företrädesr

12
May
2011

Alligator Bioscience AB genomför företrädesemission

Den 4 maj beslutade styrelsen i Alligator Bioscience AB att genomföra en företrädesemission till befintliga aktieägare. Kursen för emissionen

11
May
2011

Kallelse till årsstämma i Alligator Bioscience AB

Aktieägarna i Alligator Bioscience AB (publ) kallas till årsstämma torsdagen den 9 juni 2011, kl. 16.00, i bolagets lokaler, Scheelevägen 19A

31
Mar
2011

Alligator Bioscience AB raises 43 MSEK in directed new share issue

March 31st , 2011 Alligator Bioscience AB has raised 43 MSEK in a new round of equity financing. Mainly new institutional investors participated in

08
Feb
2011

Peter Benson, new associated member of Board of Directors, Alligator Bioscience AB

Peter Benson, new associated member of Board of Directors (Sw. adjungerad ledamot) at Alligator Bioscience AB On the 8th February 2011 the Boa

14
Jun
2010

Alligator Bioscience AB appoints Sibylle Lenz as Chief Executive Officer

Internationally experienced pharmaceutical executive will join Alligator Bioscience AB on 1st August 2010. Lund, Sweden, June 14th 2010 Allig

12
Apr
2010

Ledningsförändringar i Alligator Bioscience AB

Alligator Bioscience AB har under de senaste åren etablerat och utvecklat den unika FIND® teknologin för protein optimering och med hjälp av de

20
Jan
2010

Alternativa aktiemarknadens initiativ

Alternativa aktiemarknadens initiativ Alternativa aktiemarknaden har i januari 2010 beslutat inleda handel med Alligator Bioscience ABs aktier.

11
Jan
2010

Alligator Bioscience´s protein drug candidate ADC-1004

Alligator Bioscience´s protein drug candidate ADC-1004 for treatment of ischemia reperfusion (I/R) injury reduced myocardial infarct size in a por

08
Jan
2010

Alternativa Aktiemarknaden

Alternativa Aktiemarknaden har trots påtryckningar från Alligator Bioscience beslutat att ännu inte upphöra med noteringen på Alternativas han

Cancer cure is our passion - research is our foundation

Alligator´s technology platforms in brief

Alligator builds value by using its proprietary human scFv antibody library ALLIGATOR-GOLD® and the FIND® technology platform to develop innovative antibody-based immuno-oncology compounds for unmet medical needs within cancer. Alligator Bioscience is focusing on discovery and early development phases and is growing an attractive pipeline of drug development candidates in various stages of preclinical and clinical development. ALLIGATOR-GOLD® is a fully human synthetic kappa scFv library with large diversity (10 billion unique clones). ALLIGATOR-GOLD® has been validated by selection of functionally active antibodies with sub-nanomolar affinities against several targets. FIND® (Fragment Induced Diversity) technology is a powerful in vitro based antibody and protein optimization technology that creates functional libraries from which optimal variants of potential drug development candidates can be selected. ALLIGATOR-GOLD® and FIND® are fully integrated to give Alligator Bioscience the competitive advantage to develop immuno-oncology compounds with higher probability of success.

Discovering world-class immunotherapies to improve people’s lives

Pipeline

Project Molecule Target Lead OptimiZation Poc in Vivo Pre-clinical PHASE I
ADC-1013 Antibody CD40
ADC-1015 Bispecific Ab OX40/CTLA-4
ADC-1016 Bispecific Ab ND

Projects

ADC-1013

ADC-1013 is an antibody immunotherapy. ADC-1013 induce anti-tumor immune effects through the activation of CD40 on antigen-presenting cells. ADC-1013 is currently in clinical phase I: safety and tolerability is assessed in a clinical trial of late stage cancer patients at 5 clinical sites in Europe. ADC-1013 was out-licensed to Janssen Biotech in August 2015.

ADC-1015

ADC-1015 is a bispecific immuno-oncology compound. The drug candidate is based on the concept that the properties of two complementary immune activating entities, OX40 and CTLA-4, are united into one molecule to induce superior immune activation. Manufacturing for clinical trials was initiated in January 2016. ADC-1015 is currently in pre-clinical development.

ADC-1016

ADC-1016 is a bispecific tumor-localizing immunotherapy, composed of one tumor-targeting moiety and one immune activating moiety. Immune activation is dependent on binding to the tumor target which reduces the risk of systemic toxicity. ADC-1016 is in late research phase.

Tumor-directed immunotherapies for major unmet medical needs within cancer

Contact form Skicka ett meddelande

captcha

Generate code

Security code is used to prevent spam / verify that there is a man who physically fill out this form. If the code is hard to read, you can generate a new

captcha

Generera en kod

Säkerhets koden används för att förhindra spam. Om koden är svår att läsa kan du generera en ny

Location Karta